| In vitro predictors of clinical response in patients receiving interleukin-2-based immunotherapy. | |
| | |
MedLine Citation:
|
PMID: 8305539 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Treatment of cancer patients with interleukin-2 has resulted in clinical regression of metastatic disease. The ability to predict which patients will respond to therapy could result in more efficacious and possibly less toxic treatments. Hence, attempts have been made to correlate patient parameters or in vitro characteristics with clinical response to immunotherapy. Some patient factors have been identified as prognostically favorable. However, parameters modulated by interleukin-2 have not been predictive of clinical outcome. Exciting new evidence does exist regarding in vitro characteristics of tumor-infiltrating lymphocytes. Measurement of the cytolytic ability of melanoma tumor-infiltrating lymphocytes may enhance our understanding of the immune-mediated antitumor response and lead to a new generation of selective immunotherapies. |
| | |
Authors:
|
D J Schwartzentruber |
Related Documents
:
|
3586679 - Subungual melanoma: a 25-year review of cases. 15570199 - One hundred consecutive isolated limb perfusions with tnf-alpha and melphalan in melano... 23559319 - Management of synchronous colorectal liver metastases. 23134179 - Preliminary experience with ct-guided high-dose rate brachytherapy as an alternative tr... 8038599 - Isolation limb perfusion for melanoma: current trends and future directions. 11192839 - Immunohistochemical demonstration of metallothionein in eyes with choroidal melanomas. 15003889 - Gimema all - rescue 97: a salvage strategy for primary refractory or relapsed adult acu... 3972659 - Postoperative vaginal radiation in endometrial cancer using a remote afterloading techn... 21482989 - Validation of a novel staging system for disease-specific survival in patients with bre... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current opinion in oncology Volume: 5 ISSN: 1040-8746 ISO Abbreviation: Curr Opin Oncol Publication Date: 1993 Nov |
Date Detail:
|
Created Date: 1994-03-16 Completed Date: 1994-03-16 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9007265 Medline TA: Curr Opin Oncol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1055-8 Citation Subset: IM |
Affiliation:
|
National Cancer Institute, Bethesda, Maryland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Carcinoma, Renal Cell
/
therapy* Clinical Trials as Topic Humans Immunotherapy* Interleukin-2 / therapeutic use* Kidney Neoplasms / therapy* Melanoma / therapy* Predictive Value of Tests |
| Chemical | |
Reg. No./Substance:
|
0/Interleukin-2 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cellular therapy.
Next Document: Retinoids.